Based at Granta Park, Cambridge, Biocrucible are applying our novel proprietary molecular technology platform to enhance and accelerate the behaviour and kinetics of engineered biological systems. Our technology can significantly improve the performance of many processes already currently in use throughout the life science and diagnostic industries, and we anticipate novel applications as well. Our goal is to launch life science tools and other products in the very near future adding value to existing workflows, before developing out entirely new applications.
Biocrucible combines experienced Research and Development scientists, seasoned biotech management, and great ideas. The company was founded by Dr Niall Armes, previously inventor of the Recombinase Polymerase Amplification (RPA) isothermal DNA amplification technology. Niall leads the research and the company is assembling all the parts to ensure strong growth and future success in broad and valuable markets.
Biocrucible has partnered with the Gates Foundation to explore rapid molecular testing options for COVID-19 and other pathogens, which could be used in the home or in field settings.